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fatal complications than the injuries related to the broken 
retention wire [1]. Moreover, lead-related complications 
occurred less frequently than originally anticipated.
The recent advisories of the Medtronic Fidelis 
(Medtronic, Minneapolis, Minnesota) and St. Jude Riata 
(St. Jude Medical, St. Paul, Minnesota) defibrillator leads 
again emphasise the need to guide management through 
objective information. Many patients with advisory leads 
are approaching generator replacement, and one has to 
decide whether to maintain the advisory lead operational, or 
to implant a new lead. In addition, a decision should be made 
between extracting or abandoning non-functional advisory 
leads. The ‘Recommendations from the Heart Rhythm Soci-
ety Task Force on Lead Performance Policies and Guide-
lines’ lists factors that might influence these decisions [2]. 
Patient-related factors include pacemaker dependency, risk 
of life-threatening arrhythmias or of surgical revision, time 
to generator replacement, and psychological wellbeing. The 
considered lead characteristics are failure rate, predictabil-
ity and consequences of failure, and means to prevent the 
latter by reprogramming the device. In this paper, we take 
a look at the literature to arrive at an informed approach to 
patients with advisory leads.
Incidence of failure of contemporary advisory leads
To establish the electrical failure rate is not as straight-
forward as might be expected. The definition of electrical 
failure varies significantly, and consequently the reported 
incidence. This is amplified by disparities between cross-
sectional and prospective studies, and between different 
durations of follow-up (it takes years before failure rates 
diverge from other leads). In case of Riata, the failure rate 
may also differ between subtypes: Abdelhadi et al. reported 
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different electrical failure rates in 1081 patients between the 
8F and ST 7F leads of 8 and 1.6 %, respectively, but with a 
different median follow-up of 4.2 and 3.3 years [3]. Lastly 
there is publication bias, as initially more extreme outcomes 
are published [4].
Publications from larger cohorts approximate more 
closely the Riata lead failure rate. Parkash et al. followed 
4358 Riata leads with a median dwell time of 5.0 years, 
and found 5.2 and 3.3 % electrical failures in the 8F and 
ST 7F subtypes, respectively [5]. Hayes and colleagues pro-
spectively followed 776 patients during 9.8 ± 2.0 months of 
follow-up, and found 1.3 % electrical lead failure with no 
significant differences between Riata 8F and ST 7F leads 
[4]. These failure rates are actually in line with historic defi-
brillator lead performance [6, 7].
The externalisation of the conductors in Riata leads 
should not be confused with electrical dysfunction, as most 
researchers found the latter to be independent of externali-
sation [4, 5, 8]. Only Theuns et al. registered more elec-
trical failures with externalised conductors (10.9 vs. 3.5 %) 
[9]. However, in absolute numbers, the majority of failures 
occur in leads without externalised conductors.
The Medtronic Fidelis electrical failure rate is higher 
than the Riata failure rate: 9.1 % after 5 years in the 21,500 
patients followed in the Medtronic Care Link PLUS data, 
and 16.8 % during the same follow-up in a Canadian cohort 
of 3126 patients [10, 11].
Mortality and lead failure
It may be obvious that lead failure is not equivalent to mor-
tality, but it is surprising that quantification of mortality 
seems to be elusive, even if more than 200,000 Fidelis and 
Riata leads each have been implanted. Hauser et al. screened 
the FDA Maude database (a databank of voluntary reports 
of device malfunctions), and found 22 patients in whom the 
demise could be linked with Riata lead failure [12]. How-
ever, the same report also mentioned five Medtronic Sprint 
Quattro leads related to mortality. The lack of a denomina-
tor in these case reports obscures the real incidence of mor-
tality, as voluntary reporting may be biased towards more 
scrutiny for leads under advisory.
Only a single comparative study addressed the survival 
of patients with advisory leads vs. other leads, but found 
no difference in adjusted survival between the Medtronic 
Fidelis or the Sprint Quattro lead [13]. Moreover, in spite of 
the many publications on both Fidelis and Riata leads, mor-
tality attributed to lead failure is seldom observed: only Par-
kash et al. mentioned one death out of 4358 Riata patients 
related to lead failure [5]. It should be noted that until now 
no mortality has been linked with conductor externalisation 
of Riata leads. In practice, the true mortality rate of advi-
sory leads may remain elusive, as it would require system-
atic post-mortem interrogation of devices to separate it from 
the substantial natural attrition in a typical ICD population.
Only patients who would die in the absence of a work-
ing defibrillator are at risk from lead failure: in populations 
similar to the SCD-HeFT and MADIT II cohorts, this would 
account for 2–3 % every year (6 % mortality reduction in 
SCD-HeFT during a 3-year follow up, and 6.4 % in MADIT 
II after 2 years) [14–16]. In case of Fidelis leads and assum-
ing a lead failure rate of 3 % per year, the natural attrition 
of around 5 % per year, and malfunctioning leads being 
replaced after routine controls or inappropriate shocks, 
some approximating calculus will show that the mortality 
risk is less than 0.1 % per year [15–17].
Morbidity
The most debilitating complication of advisory lead failure 
is inappropriate shocks from lead noise that is considered 
to be an arrhythmia by the ICD. But this is not exclusive 
for recalled leads, as these shocks occurred even with con-
servative programming in the first year after implant in 3.6 
and 3.0 %, respectively, of patients in the PREPARE and 
MADIT-RIT study [18, 19]. A single-centre Dutch study fol-
lowing 1075 implants reported a 3 % incidence after 31 ± 17 
months of follow-up [20]. In comparison, even though the 
mode of presentation in about half of the defective Fidelis or 
Riata leads is inappropriate shocks, the absolute incidence 
ranges from only 0.7 to 3.6 % of all implanted leads [5, 11, 
21, 22].
In the PREPARE and MADIT-RIT studies, the cause of 
inappropriate shocks is mostly supraventricular tachycardia 
and not lead noise. It is therefore uncertain whether lead-
related inappropriate shocks have the same impact on sur-
vival as in these studies [19, 23].
Inappropriate shocks can have a profound influence on 
the psychological wellbeing of the patient. There is a sig-
nificant relation in the general ICD population between 
procedure-related complications and anxiety, but not with 
depression [24]. Compared with patients with non-advisory 
leads, patients with uncomplicated advisory leads show no 
difference in psychological functioning [25]. Notwithstand-
ing the often dramatic presentation of inappropriate shocks 
in clusters and during full consciousness, literature is not 
unequivocal about the long-term influence on psychological 
wellbeing. Actually, only a few small studies have addressed 
the impact on anxiety and depression. Only one out of five 
showed a significant difference in depression scores, and a 
minority of seven studies a small to moderate difference in 
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will also foreshorten the lifecycle of the generator as it is 
often concurrently replaced, and this adds to the cost of the 
therapy.
It may be more favourable to replace advisory leads dur-
ing elective generator replacement, as only the additional 
risk of inserting a new lead has to be accounted for. Bashir 
et al. calculated the cost and effectiveness of a proactive 
lead replacement strategy at the time of an elective genera-
tor replacement for patients under 60 years, with normally 
functioning Sprint Fidelis leads, and an expected failure rate 
of 5.2 % per year as observed in their population [17]. Even 
when the cost of elective lead extraction in one-third of the 
procedures was included, they still prove that the proactive 
strategy was more cost-effective than waiting for lead failure 
to occur. Also 21 impromptu lead failures per 100 patients 
were avoided, and this limited morbidity and unscheduled 
interventions. This benefit is influenced by the incidence of 
failure, the ratio of leads extracted during replacements, and 
individual patient profiles.
Implanting a totally subcutaneous defibrillator or S-ICD 
in eligible patients could be an alternative as transvenous 
lead introduction is avoided. This approach introduces 
additional surgery, as the depleted generator still has to be 
removed. Moreover, on-going studies such as the PRAETO-
RIAN trial have to prove that the complication rate includ-
ing the incidence of inappropriate shocks, shock efficiency 
and mortality is on par with current transvenous ICD sys-
tems [35].
Extracting or abandoning non-functional leads
The expert consensus of the Heart Rhythm Society on lead 
extraction states that non-functional leads that interfere with 
the operation of implanted devices have a class I indica-
tion for extraction, and non-functional leads that pose no 
immediate threat to the patient a class IIb indication [36]. 
Both have a level of evidence C, and this is also reflected 
by Maytin et al. who mentioned that the risk of abandon-
ing non-functional leads is considered ‘to be real’ by most 
lead extraction experts, although the latter have to admit 
to the lack of evidence [37]. In the consensus paper it is 
noted that many important clinical questions have not yet 
been addressed by high-quality investigations, or do not 
lend themselves to experimentation. The expert opinion is 
based on the assumptions that removing leads is necessary 
to avoid electrical interference, to prevent accumulation of 
abandoned leads that predisposes to venous occlusion, and 
to avert more difficult future extractions from increasing 
dwell times.
In contrast to this, all published reports indicate the safety 
of abandoning non-functional leads. Interference with aban-
doned leads is in most cases easily avoided if integrated 
The activation of lead integrity alerts and programming 
longer detection intervals have significantly reduced the 
incidence of inappropriate shocks. Kallinen et al. reported 
a reduction of shocks from 69 to 17 %, and of the average 
number of shocks in a cluster from 13 to 3, and Swerdlow 
et al. a 46 % shock reduction and a more than 50 % reduction 
in clusters of more than 5 shocks [27, 28]. The PREPARE 
and MADIT-RIT trials have demonstrated that allowing 
more time for spontaneous termination of arrhythmia by 
programming longer detection parameters resulted in a sub-
stantial reduction of inappropriate therapy [18, 19]. How-
ever, implementing these interventions should be standard 
practice in every ICD patient.
Pacing dependent patients may be more directly affected 
by lead failure through inhibition of pacing from noise 
detection, or non-capture from lead fracture. Symptom-
atic inhibition of pacing or failure to capture is nonetheless 
only sporadically observed. Hauser et al. reported failure 
to pace in 13 out of 848 patients with a Fidelis lead. Only 
one patient experienced syncope but there was no mortal-
ity [29]. In a Canadian study, 11 out of 3169 patients with 
Fidelis leads had symptomatic inhibition of pacing, also 
without mortality [11]. This may seem reassuring at first 
sight, but patients without any intrinsic rhythm are probably 
more at risk of asystole in case of lead malfunction than of 
ventricular fibrillation at any time.
Proactively replacing advisory leads
Dysfunctional leads are to be replaced when continuation of 
(reliable) defibrillator therapy is required. However, there 
are no studies that compare the preventive replacement of a 
still normally functioning advisory lead with a wait-and-see 
approach.
Adding any new lead, or even replacing the generator, is 
not without complications. The Danish pacemaker registry 
reported a 2.9 % infection rate after elective pacemaker gen-
erator exchange in 8380 patients [30]. Replacing advisory 
ICD generators in 533 patients in a Canadian study resulted 
in more complications than from device malfunction: 5.8 % 
major complications, including two deaths from lead extrac-
tion because of infection [31]. Also Costea et al. reported 
4.1 % major complications after replacing advisory genera-
tors [32].
The REPLACE study demonstrated that inserting an 
additional lead (excluding upgrades to cardiac resynchro-
nisation therapy) had a major complication rate of 12.7 % 
in contrast to 4.9 % if only the generator was exchanged 
[33]. Eckstein et al. reported an eight-fold increase of lead 
complications after implanting new shock or pace-sense 
leads after lead failure when compared with only exchang-
ing the generator [34]. Many of the premature interventions 
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isation of the conductors may result in ‘snowploughing’ of 
the insulation material in front of the extraction sheaths. The 
8F Riata shock coils also lack backfilling, which may result 
in more ingrowth of scar tissue. This correlates well with 
the need of powered extraction sheaths in 18 out of 20 Riata 
patients by Patel et al., and in 60 % of procedures by Maytin 
et al. (the latter with a mean dwell time of only 42 months) 
[37, 52]. In a mixed population of Fidelis and Riata, Brun-
ner et al. needed powered sheaths in 83.7 % of 430 cases 
with a median implant time of less than 5 years [53].
Some authors suggest that the risk of extracting advisory 
leads is low provided it is executed in experienced centres 
and in patients without comorbidities, but this is not con-
firmed by the data. Parkash et al. experienced major com-
plications in 8.1 % of patients including one death during 
extraction of a Fidelis lead [51]. Brunner et al. reported 
that safety and efficacy was comparable with that of a non-
recalled ICD lead (0.4 % mortality in their centre), but they 
still experienced two fatal complications: one out of 121 
Riata leads, and one out of 308 Fidelis leads [53, 54]. There 
is often no motivation provided why some advisory leads are 
extracted and others abandoned. Parkash et al. performed 
formal extraction of 248 Fidelis leads, but abandoned 51 
leads after simple traction failed, and did not attempt extrac-
tion in 169 leads, but the authors did not discuss the indica-
tion [51]. In order to estimate the risk of lead extraction, 
the reader should not be deceived by the published overall 
results of lead extraction, as these are often dominated by 
much shorter implant times than current advisory leads.
Conclusion
Although there is a potential risk of lethal complications 
from current advisory leads, there is no indication that it 
surpasses that of prematurely replacing these leads. How-
ever, a scheduled generator exchange may be an opportune 
moment to consider adding a new defibrillator lead with 
established reliability with a limited additional risk. Still, 
there are no data or guidelines on what exact lead failure 
rate justifies this approach.
The accumulative risk of lead failure during the service 
time of an ICD increases with the expected longer battery 
life of current devices. Together with the failure rate of the 
Fidelis leads, it favours lead replacement during a generator 
exchange in our opinion. In contrast, it may be less ben-
eficial with the currently observed electrical defects of the 
Riata leads. Independent and prospective collection of data 
on lead performance is needed for continuing evaluation of 
changing risk profiles.
Individual patient profiles influence the approach: in 
elderly patients the risk of failure may be lower, time at risk 
shorter, and procedural risks higher. In contrast, frequent 
bipolar leads are not used to avoid contact between coils that 
may result in oversensing. Sung et al. observed no adverse 
events attributable to interaction between newly implanted 
and abandoned Riata leads in 29 patients [22]. Bohm et al. 
remarked that no complications occurred after they started 
securing the (pacemaker) leads to prevent migration, and 
capping them to avoid electrical interference [38]. Suga 
et al. followed 531 patients with abandoned pacing leads, 
of whom only 18 needed extraction: in 7 because of venous 
obstruction to gain vascular access and in 8 owing to infec-
tion [39]. Likewise, Glikson et al., Bode et al. and Amelot et 
al. did not find any clinically significant risk from abandon-
ing defibrillator leads in 78, 60 and 37 patients, respectively 
[40–42].
There has never been proof of a link between venous 
obstruction and the number of indwelling leads, and lead 
extraction itself has not been cleared from predisposing to 
this complication [43, 44]. In fact, when advisory leads are 
replaced with leads with established low failure rates, only a 
minority of patients will need future additional leads. Throm-
bus formation has been reported with externalised conduc-
tors of a Riata lead, but this is not exclusive to this type of 
lead [45–47]. Although extreme externalisation of Riata leads 
has been suggested to be potentially dangerous, there are no 
reports of clinical complications from this phenomenon.
Venkataraman et al. calculated that extraction of all non-
functional sterile leads in order to prevent venous occlusion 
compared with extraction reserved for patients who present 
with occlusion (with an estimated incidence of 5 %) would 
result in a ten-fold higher mortality, even considering a dou-
bled mortality rate because of longer dwell times [48]. If a 
similar calculation is made for infection, with an estimated 
incidence between 2–3 % after any surgical intervention, 
preventive extraction will likewise have a higher mortality 
than when extraction is limited to infected leads [30, 36]. 
A conservative approach also avoids unnecessary extrac-
tion procedures in more than 95 % of patients, and hereby 
considerably reduces the cost of managing advisory leads: 
Mehrotra et al. calculated an additional cost of $ 12,000 to 
$ 13,000 per extraction procedure compared with abandon-
ing the leads [49]. Bashir et al. calculated that extraction 
of two-thirds of the leads in the setting of proactive replac-
ing advisory leads at the time of generator exchange would 
result in an incremental cost of $ 12,779 per ICD lead fail-
ure avoided [17].
Extraction of advisory leads is not as easy as often sug-
gested. Specialised tools, such as laser sheaths, are fre-
quently necessary to extract Fidelis leads notwithstanding 
relatively short dwell times: in 51 % of the extractions by 
Maytin et al. and in 33 % by Parkash et al. with implant 
times of a mean 28 months or less than 4 years, respec-
tively [50, 51]. Extraction of Riata leads may be even more 
demanding, as breach of the insulation material by external-
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need for defibrillator therapy, true pacing dependency, or the 
psychological burden of living with an advisory lead, may 
incline us to replace the lead.
Finally, there is no support in the literature for preven-
tive extraction of sterile, non-functional (advisory) leads. In 
contrast, lead extraction has a definite risk of mortality and 
morbidity that is absent when leads are properly abandoned.
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